Related Experiment Video

Updated: Nov 3, 2025

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.4K

Targeting the VEGF Pathway in Osteosarcoma

Tarek Assi1, Sarah Watson2, Bachar Samra3

  • 1Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon.

Cells
|June 2, 2021
PubMed

Insights

Targeting angiogenesis via the VEGF pathway shows promise for osteosarcoma treatment. This review explores targeted agents and clinical trials for relapsed or metastatic osteosarcoma, offering hope for improved patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Osteosarcoma is the most common primary bone tumor in young adults.
  • Metastatic or relapsed osteosarcoma has a poor prognosis despite current therapies.
  • Increased angiogenesis is crucial for osteosarcoma growth and survival.

Purpose of the Study:

  • To review the role of targeting angiogenesis via the VEGF pathway in osteosarcoma.
  • To discuss the pathophysiology and rationale for anti-angiogenic therapy.
  • To summarize clinical trials and future directions for VEGF pathway inhibition.

Main Methods:

  • Literature review of published clinical trials.
  • Analysis of the role of angiogenesis in osteosarcoma pathophysiology.
  • Discussion of targeted agents, including multi-kinase inhibitors.

Main Results:

  • Targeted agents inhibiting angiogenesis, particularly via the VEGF pathway, show significant anti-tumor activity.
  • Multi-kinase inhibitors have demonstrated efficacy in osteosarcoma.
  • Clinical trials provide evidence for the potential of these targeted therapies.

Conclusions:

  • Targeting the VEGF pathway is a promising strategy for osteosarcoma treatment.
  • Further clinical trials are needed to optimize anti-angiogenic therapies.
  • Understanding osteosarcoma pathophysiology aids in developing novel targeted agents.
Keywords:
angiogenesisbone neoplasmsosteosarcomaprotein kinase inhibitorssarcomavascular endothelial growth factor A

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.9K
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K